2 results match your criteria: "S. Gerardo Hospital-University of Milano-Bicocca[Affiliation]"
Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy.
Front Med (Lausanne)
March 2022
Italian Association of Pediatric Hematology Oncology (AIEOP) Coagulation Disorders Working Group, Brescia, Italy.
Unlabelled: Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder characterized by recurrent acute vaso-occlusive crises (VOCs and anemia). Gold standard treatments are hydroxycarbamide (HC) and/or different red blood cell (RBC) transfusion regimens to limit disease progression. Here, we report a retrospective study on 1,579 SCD patients (median age 23 years; 802 males/777 females), referring to 34 comprehensive Italian centers for hemoglobinopathies.
View Article and Find Full Text PDFIn vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Cancer Res
December 2006
Department of Clinical Medicine, S. Gerardo Hospital-University of Milano-Bicocca, Monza, Italy.
Article Synopsis
- Resistance to imatinib is a significant challenge in treating chronic myelogenous leukemia (CML), prompting research into alternatives like the novel inhibitor SKI-606.
- SKI-606 demonstrated strong inhibition of Bcr-Abl in CML cell lines, outperforming imatinib by being effective even at lower concentrations, while not targeting other forms of resistance.
- In vivo studies showed that SKI-606 remained effective against various mutations and amplification that confer imatinib resistance, suggesting its unique binding ability to Bcr-Abl could provide a new therapeutic strategy.